

RECOMBINANT ANTIBODIES FOR IMMUNOTHERAPY

Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-four chapters by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, “arming” mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field.

The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors.

Melvyn Little’s research group at the German Cancer Research Center (DKFZ) in Heidelberg was one of the first to develop methods for making and screening antibody libraries. After co-founding Affitech (Oslo, Norway) in 1997, he left the DKFZ in 2000 to found Affimed Therapeutics, a biotechnology company in Heidelberg specializing in the isolation and engineering of human antibodies to treat various diseases, especially cancer. He has been an extracurricular professor of biochemistry at the University of Heidelberg since 1986.

RECOMBINANT ANTIBODIES FOR IMMUNOTHERAPY

Edited by

Melvyn Little

Affimed Therapeutics



CAMBRIDGE
UNIVERSITY PRESS

Cambridge University Press & Assessment
978-0-521-88732-8 — Recombinant Antibodies for Immunotherapy
Edited by Melvyn Little
Frontmatter
[More Information](#)



Shaftesbury Road, Cambridge CB2 8EA, United Kingdom
One Liberty Plaza, 20th Floor, New York, NY 10006, USA
477 Williamstown Road, Port Melbourne, VIC 3207, Australia
314–321, 3rd Floor, Plot 3, Splendor Forum, Jasola District Centre, New Delhi – 110025, India
103 Penang Road, #05–06/07, Visioncrest Commercial, Singapore 238467

Cambridge University Press is part of Cambridge University Press & Assessment, a department of the University of Cambridge.
We share the University’s mission to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence.

www.cambridge.org
Information on this title: www.cambridge.org/9780521887328

© Cambridge University Press & Assessment 2009
This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press & Assessment.
First published 2009
A catalogue record for this publication is available from the British Library

Library of Congress Cataloging-in-Publication data
Recombinant antibodies for immunotherapy / edited by Melvyn Little.
p. ; cm.

Includes bibliographical references and index.
ISBN 978-0-521-88732-8 (hardback)
1. Monoclonal antibodies – Therapeutic use. I. Little, Melvyn, 1945– II. Title.
[DNLN: 1. Immunotherapy – methods. 2. Antibodies, Monoclonal – therapeutic use.
3. Recombinant Proteins – therapeutic use. QW 940 R311 2009]

RM282.M65R43 2009
615'.37 – dc22 2008044201
ISBN 978-0-521-88732-8 Hardback

Cambridge University Press & Assessment has no responsibility for the persistence or accuracy of URLs for external or third-party internet websites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate. Information regarding prices, travel timetables, and other factual information given in this work is correct at the time of first printing but Cambridge University Press & Assessment does not guarantee the accuracy of such information thereafter.

.....
Every effort has been made in preparing this book to provide accurate and up-to-date information which is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.

Contents

Contributors	page vii
Foreword by Sir Gregory Winter	xi
Preface	xiii
PART I. HUMANIZED ANTIBODIES	
1 Humanization of Recombinant Antibodies <i>José W. Saldanha</i>	3
2 Immunogenicity Assessment of Antibody Therapeutics <i>Philippe Stas, Jurgen Pletinckx, Yannick Gansemans, and Ignace Lasters</i>	20
3 <i>In Vitro</i> Screening for Antibody Immunogenicity <i>Frank J. Carr and Matthew P. Baker</i>	43
PART II. GENERATION AND SCREENING OF ANTIBODY LIBRARIES	
4 Antibody Libraries from Naïve V Gene Sources <i>Gerald Beste and David Lowe</i>	55
5 Antibodies from IgM Libraries <i>Stefan Knackmuss and Vera Molkenhain</i>	66
6 Generation and Screening of the Synthetic Human Combinatorial Antibody Library HuCAL GOLD <i>Ingo M. Klagge</i>	75
PART III. TRANSGENIC HUMAN ANTIBODY REPERTOIRES	
7 Therapeutic Antibodies from XenoMouse Transgenic Mice <i>Aya Jakobovits</i>	89
8 VelocImmune: Immunoglobulin Variable Region Humanized Mice <i>Andrew Murphy</i>	100
PART IV. ANTIBODY EFFECTOR FUNCTION	
9 Mechanisms of Tumor Cell Killing by Therapeutic Antibodies <i>Ross Stewart and Carl Webster</i>	111
10 Optimization of Fc Domains to Enhance Antibody Therapeutics <i>Greg A. Lazar and Aaron K. Chamberlain</i>	124
11 Glycoengineered Therapeutic Antibodies <i>Peter Brünker, Peter Sondermann, and Pablo Umaña</i>	144

PART V. ARMING ANTIBODIES		
12	Monoclonal Antibodies for the Delivery of Cytotoxic Drugs <i>David J. King</i>	157
13	Immunotherapy with Radio-immune Conjugates <i>Christina A. Kousparou and Agamemnon A. Epenetos</i>	174
14	Immunotherapeutic Antibody Fusion Proteins <i>Nigel S. Courtenay-Luck and David Jones</i>	190
PART VI. NOVEL ANTIBODY FORMATS		
15	Alternative Antibody Formats <i>Fabrice Le Gall and Melvyn Little</i>	203
16	Single-Domain Antibodies <i>Serge Muyldermans, Gholamreza Hassanzadeh Ghassabeh, and Dirk Saerens</i>	216
17	Engineering of Non-CDR Loops in Immunoglobulin Domains <i>Florian Rüker and Gordana Wozniak-Knopp</i>	231
PART VII. ANTIGEN-BINDING REPERTOIRES OF NON-IMMUNOGLOBULIN PROTEINS		
18	Alternative Scaffolds: Expanding the Options of Antibodies <i>Andreas Plückthun</i>	243
PART VIII. PROLONGATION OF SERUM HALF-LIFE		
19	Polymer Fusions to Increase Antibody Half-Lives: PEGylation and Other Modifications <i>Sam P. Heywood and David P. Humphreys</i>	275
20	Extending Antibody Fragment Half-Lives with Albumin <i>Jan Terje Andersen and Inger Sandlie</i>	293
PART IX. INNOVATIVE IMMUNOTHERAPEUTIC APPROACHES		
21	A Stem Cell–Based Platform for the Discovery and Development of Antitumor Therapeutic Antibodies to Novel Targets <i>Jennie P. Mather, Claudia Fieger, Tony W. Liang, Kathleen L. King, Jonathan Li, Peter Young, Claude Beltejar, Beverly Potts, Monica Licea, and Deryk Loo</i>	313
22	Antibody Directed Enzyme Prodrug Therapy (ADEPT) <i>Helen L. Lowe, Surinder K. Sharma, Kenneth D. Bagshawe, and Kerry A. Chester</i>	336
23	Immune Privilege and Tolerance – Therapeutic Antibody Approaches <i>Daron Forman, Paul Ponath, Devangi Mehta, Joe Ponte, Jessica Snyder, Patricia Rao, Herman Waldmann, and Michael Rosenzweig</i>	350
PART X. MARKET OVERVIEW AND OUTLOOK		
24	Antibody Therapeutics: Business Achievements and Business Outlook <i>Christophe Bourrilly</i>	373
	Index	403
<i>Color plates follow page xvi.</i>		

Contributors

Jan Terje Andersen
*Department of Molecular Biosciences and
Centre for Immune Regulation
University of Oslo
Oslo, Norway*

Kenneth D. Bagshawe
*Department of Oncology
Imperial College London
London, U.K.*

Matthew P. Baker
*Antitope Ltd.
Babraham, Cambridge, U.K.*

Claude Beltejar
*Raven Biotechnologies
San Francisco, California, U.S.*

Gerald Beste
*formerly MedImmune Ltd.
Cambridge, U.K.
now Ablynx NV
Ghent, Belgium*

Christophe Bourrilly
*ABN AMRO Corporate Finance Ltd.
London, U.K.*

Peter Br unker
*Glycart Biotechnology (Roche Group)
Schlieren, Switzerland*

Frank J. Carr
*Antitope Ltd.
Babraham, Cambridge, U.K.*

Aaron K. Chamberlain
*Xencor
Monrovia, California, U.S.*

Kerry A. Chester
*CR UK Targeting & Imaging Group
Department of Oncology
UCL Cancer Institute
University College London
London, U.K.*

Nigel S. Courtenay-Luck
*Antisoma Research Ltd.
London, U.K.*

Agamemnon A. Epenetos
*Trojanterc Ltd.
Nicosia, Cyprus*

Claudia Fieger
*Raven Biotechnologies
San Francisco, California, U.S.*

Daron Forman
*Tolerx
Cambridge, Massachusetts, U.S.*

Yannick Gansemans
*Algonomics NV
Gent-Zwijnaarde, Belgium*

Gholamreza Hassanzadeh Ghassabeh
*Laboratory of Cellular and Molecular
Immunology
Vrije Universiteit
and Department of Molecular and Cellular
Interaction
VIB
Brussels, Belgium*

Sam P. Heywood
*Antibody Research
UCB-Celltech
Slough, U.K.*

David P. Humphreys
Antibody Research
UCB-Celltech
Slough, U.K.

Aya Jakobovits
Agensys, Inc.
Santa Monica, California, U.S.

David Jones
Antisoma Research Ltd.
London, U.K.

David J. King
formerly Medarex
Sunnyvale, California, U.S.
now AnaptysBio Inc.
San Diego, California, U.S.

Kathleen L. King
Raven Biotechnologies
San Francisco, California, U.S.

Ingo M. Klagge
MorphoSys AG
Martinsried/Planegg, Germany

Stefan Knackmuss
Affimed Therapeutics AG
Heidelberg, Germany

Christina A. Kousparou
Trojantec Ltd.
Nicosia, Cyprus

Ignace Lasters
Algonomics NV
Gent-Zwijnaarde, Belgium

Greg A. Lazar
Xencor
Monrovia, California, U.S.

Fabrice Le Gall
Affimed Therapeutics AG
Heidelberg, Germany

Jonathan Li
Raven Biotechnologies
San Francisco, California, U.S.

Tony W. Liang
Raven Biotechnologies
San Francisco, California, U.S.

Monica Licea
Raven Biotechnologies
San Francisco, California, U.S.

Melvyn Little
Affimed Therapeutics AG
Heidelberg, Germany

Deryk Loo
Raven Biotechnologies
San Francisco, California, U.S.

David Lowe
MedImmune Ltd.
Cambridge, U.K.

Helen L. Lowe
CR UK Targeting & Imaging Group
Department of Oncology
UCL Cancer Institute
University College London
London, U.K.

Jennie P. Mather
Raven Biotechnologies
San Francisco, California, U.S.

Devangi Mehta
Tolerx
Cambridge, Massachusetts, U.S.

Vera Molkenthin
Affimed Therapeutics AG
Heidelberg, Germany

Andrew Murphy
Regeneron
Tarrytown, New York, U.S.

Serge Muyldermans
Laboratory of Cellular and Molecular Immunology
Vrije Universiteit
and Department of Molecular and Cellular Interaction
VIB
Brussels, Belgium

Contributors

- Jurgen Pletinckx**
Algonomics NV
Gent-Zwijnaarde, Belgium
- Andreas Plückthun**
Department of Biochemistry
University of Zürich
Zurich, Switzerland
- Paul Ponath**
Tolerx
Cambridge, Massachusetts, U.S.
- Joe Ponte**
Tolerx
Cambridge, Massachusetts, U.S.
- Beverly Potts**
Raven Biotechnologies
San Francisco, California, U.S.
- Patricia Rao**
formerly Tolerx
Cambridge, Massachusetts, U.S.
now Synta Pharmaceutical Corp.
Lexington, Massachusetts, U.S.
- Michael Rosenzweig**
Tolerx
Cambridge, Massachusetts, U.S.
- Florian Rüker**
Department of Biotechnology
University of Natural Resources
and Applied Life Sciences
Vienna, Austria
- Dirk Saerens**
Laboratory of Cellular and Molecular
Immunology
Vrije Universiteit
and Department of Molecular and Cellular
Interaction
VIB
Brussels, Belgium
- José W. Saldanha**
Division of Mathematical Biology
National Institute for Medical Research
Mill Hill, London, U.K.

- Inger Sandlie**
Department of Molecular
Biosciences and Centre for Immune Regulation
University of Oslo
Oslo, Norway
- Surinder K. Sharma**
CR UK Targeting & Imaging Group
Department of Oncology
UCL Cancer Institute
University College London
London, U.K.
- Jessica Snyder**
Tolerx
Cambridge, Massachusetts, U.S.
- Peter Sonderrmann**
Glycart Biotechnology (Roche Group)
Schlieren, Switzerland
- Philippe Stas**
Algonomics NV
Gent-Zwijnaarde, Belgium
- Ross Stewart**
MedImmune Ltd.
Cambridge, U.K.
- Pablo Umaña**
Glycart Biotechnology (Roche Group)
Schlieren, Switzerland
- Herman Waldmann**
formerly Tolerx
Cambridge, Massachusetts, U.S.
now Sir William Dunn School of Pathology
Oxford, U.K.
- Carl Webster**
MedImmune Ltd.
Cambridge, U.K.
- Gordana Wozniak-Knopp**
Department of Biotechnology
University of Natural Resources
and Applied Life Sciences
Vienna, Austria
- Peter Young**
Raven Biotechnologies
San Francisco, California, U.S.

Foreword

Antibodies were discovered in 1890 but remained on the periphery of the pharmaceutical industry for more than 100 years. Yet within the last 15 years, a succession of antibodies has been approved for therapy by the United States Food and Drug Administration (FDA). Unlike natural antibodies which are polyclonal and directed against infectious disease, almost all those approved by the FDA are monoclonal antibodies directed against human self-antigens and used for treatment of cancer and diseases of the immune system.

Two major breakthroughs proved necessary to launch this antibody revolution. The first breakthrough was rodent hybridoma technology in the 1970s. Antibodies could now be made against single antigens in complex mixtures and used to identify the molecular targets of disease. In some cases this allowed disease intervention by blocking the antigen or by killing a class of cells (such as cancer cells) bearing the antigen. However, hybridoma technology provided only part of the solution; the rodent antibodies proved immunogenic and often did not trigger human effector functions efficiently. The second breakthrough, in the 1990s, was protein engineering; its application allowed the creation of chimeric and humanized antibodies from rodent monoclonal antibodies; not only were these less immunogenic than rodent antibodies, but they more efficiently triggered human effector functions. These chimeric and humanized antibodies now account for the majority of the currently approved therapeutic antibodies.

Nevertheless the field continued to embrace new technologies and to spawn new approaches, most notably the development of genuine human antibodies in the 1990s. Human therapeutic antibodies were made by selection from highly diverse antibody repertoires displayed on filamentous phage, and then from mice transgenic with human antibody genes. The pace of innovation continued in the new millennium; antibodies were built from single domains, endowed with enhanced effector functions or prolonged serum half-life, and even tailored to bind antigen via engineered constant domains. Earlier approaches, for example those based on cytotoxic drugs or radio-immune conjugates, were also re-evaluated. In a field with few clinically validated targets and a thicket of intellectual property, technological innovation has offered freedom for new biotechnology companies to develop therapeutics based on antibodies or antibody mimics.

Recombinant Antibodies for Immunotherapy, edited by Professor Melvyn Little, covers both the fundamentals of the technology and the current state of its

development and concludes with a section on novel therapeutic approaches and an overview of the market that has driven, and continues to drive, the field. The book promises to be an essential and most convenient guide to the field.

Sir Gregory Winter FRS
Deputy Director
Laboratory of Molecular Biology and MRC Centre for Protein Engineering
Cambridge, UK

Preface

The potential of antibodies as magic bullets for curing disease has excited the imagination of medical researchers ever since this phrase was first coined by Paul Ehrlich about a century ago. Seventy-five years after the publication of Ehrlich's side-chain theory to explain antibody-antigen reactions in 1900, Georges Köhler and César Milstein invented a means of cloning antibodies with defined specificity that paved the way for major advances in cell biological and clinical research. They were awarded the Nobel Prize in Medicine in 1984 for this ground-breaking research. In 1986, the first monoclonal antibody, the murine mAb OKT3 for preventing transplant rejection, was approved for clinical use, and although many other murine mAbs were subsequently investigated as therapeutic agents, most of them had a disappointing clinical profile largely due to their immunogenicity. This situation improved dramatically with the advent of techniques to humanize existing mAbs, followed by technologies that sought to imitate the generation of specific antibodies by the immune system *in vitro*. For example, the expression of antibody fragments in *E. coli* using bacterial leader sequences and the use of phage display and later ribosome display facilitated the selection of specific human antibodies from extremely large libraries. The process of somatic hypermutation to increase antibody affinity was mimicked by introducing random mutations. Another major advance for obtaining human antibodies was the creation of transgenic mice carrying a large part of the human antibody gene repertoire, which could be used to produce human antibodies by standard hybridoma technology. The success of these novel technologies resulted in a first generation of recombinant antibodies that now account for a large proportion of the market for biopharmaceuticals, with annual growth rates of almost 40%.

Therapeutic antibodies for cancer rely to a large extent on the recruitment of other elements in the immune system for their effect; very few of them function as magic bullets in the sense of "target and destroy." For example, although antibody binding to a specific epitope of a cell surface receptor can directly induce strong apoptotic signals, the effect is usually amplified by cross-linking of the antibody Fc domains through binding to Fc receptors on immune effector cells such as macrophages and natural killer cells. Concomitantly, the immune effector cells are activated by the engagement of the Fc receptors, resulting in an attack on the cells to which they are bound, a process known as antibody-dependent cell cytotoxicity (ADCC). The Fc domains can also activate the complement system, causing complement-dependent cytotoxicity (CDC). To what extent cell lysis is caused by direct binding and how much is due to the recruitment of immune effector cells and complement is difficult to quantify, especially in an *in vivo* system, and in many cases the mechanism of action of

antitumor antibodies remains ill defined. For the action of most cytolytic antibodies, all three mechanisms are probably involved to a lesser or greater extent. Furthermore, recent findings suggest that ADCC also contributes to the efficacy of those antibodies that were previously thought to cause tumor regression solely by blocking the ligand-binding site of growth hormone receptors.

In the second generation of therapeutic recombinant antibodies now in various stages of development, novel techniques and creative antibody engineering have evolved to optimize pharmacokinetic and pharmacodynamic properties. For example, the affinity of antibody Fc domains for their receptors on immune effector cells or to complement has been improved by both random and targeted mutagenesis. Cell lines have also been generated for altering the glycosyl side chains on the Fc domains for better Fc-receptor binding. Algorithms and *in vitro* techniques have been devised for predicting immunogenicity and selecting the best variants. In addition, the cytotoxic potential of antibodies and antibody fragments has been increased by arming them with toxins, radionuclides, or immune effector molecules such as cytokines. A large number of novel antibody formats ranging from single variable domains of approximately 13kDa to full-length antibodies with multiple variable domains of approximately 200kDa have been constructed to enable a variety of different functions. For example, bispecific antibodies for recruiting T cells to lyse tumor cells have been engineered without constant domains, thus reducing the risk of cytokine storms due to extensive cross-linking with Fc receptors. Finally, a variety of novel protein scaffolds are being investigated as alternatives to immunoglobulin fragments for the generation of libraries of highly diverse binding molecules that could result in novel therapeutic drugs. However, as nearly all of the alternative binding molecules are the same size as or even smaller than single immunoglobulin domain antibodies, their serum half-lives will probably have to be significantly extended using techniques such as pegylation or fusion to serum proteins such as albumin.

All of the recombinant antibody technologies just described are covered by the 24 articles in this book, written by recognized experts in their field, many of whom have pioneered important new techniques. Starting with a description of the technologies used to generate recombinant antibodies, the following chapters provide a fairly comprehensive overview, with examples and background information, on how antibody efficacy is being improved by decreasing immunogenicity, increasing effector function through increased Fc-receptor binding, conjugating with cytolytic agents, using novel formats and scaffolds with multiple valencies and specificities, and increasing serum half-life. Several promising therapeutic approaches have been included, such as a novel method for selecting antibodies that specifically lyse tumor cells, the development of a recombinant antibody prodrug, and the use of novel recombinant antibodies that target T cells for the treatment of autoimmune disease. Last but not least, an attempt to forecast future developments in the field of therapeutic recombinant antibodies has been made on the basis of an excellent market analysis of this rapidly growing field.

M.L.